Replies to post #770651 on NorthWest Biotherapeutics Inc (NWBO)

[StockFollower]

Hi Beartrap12 - very good questions that I don't know the answers to. Hopefully someone else can address your questions.

SF

[barnstormer]

Beartrap, I don't know about EDEN, but the contraption in the pasture kind of resembles one of the machines we used to make crates for cantaloupe packing sheds during the summer while I was in high school.

[XMaster2023]

Bear trap, per Gemini,
Yes, the "Processing Instrument for Cellular Therapy Manufacturing" described in patent application WO2025106534 is different from Flaskworks, although both relate to automated cell therapy manufacturing.
Here's why and what we know about each:
Flaskworks:
* Focus: Flaskworks developed a system specifically tailored for the manufacturing of immune cells, particularly dendritic cells, aiming for scale-up and cost reduction of products like DCVax.
* Key Features: It's described as a "closed, automated perfusion cell culture system" designed to transform manual, "artisan" processes into assembly-line-like automation. It also aims to reduce the need for highly costly clean rooms by making manufacturing steps "closed."
* Ownership: Flaskworks, LLC was acquired by Northwest Biotherapeutics in 2020. Therefore, Northwest Biotherapeutics owns the Flaskworks technology and related intellectual property.
Patent Application WO2025106534 - "Processing Instrument for Cellular Therapy Manufacturing":
* Focus: This patent application describes an advanced system to "automate and optimize the production of genetically modified immune cells, such as CAR T cells." This indicates a broader scope beyond just dendritic cells, specifically mentioning CAR T cells.
* Key Findings: While the full details of the patent are not available in the provided snippet, the title and description suggest an emphasis on enhancing efficiency, consistency, and scalability in the manufacturing of genetically modified immune cells. This aligns with the general trends in cell therapy to automate and improve manufacturing processes.
* Ownership: Based on recent information, it appears that Northwest Biotherapeutics (NWBO) is the applicant for patent application WO2025106534. This suggests that the "Processing Instrument for Cellular Therapy Manufacturing" is likely a new development or an evolution of their existing efforts in cell therapy manufacturing, potentially building upon or integrating with the Flaskworks technology they acquired.
In summary:
While both Flaskworks and the technology in patent WO2025106534 aim to automate and improve cell therapy manufacturing, the patent describes a system more broadly focused on genetically modified immune cells like CAR T cells, whereas Flaskworks was specifically highlighted for its application to dendritic cells. However, since Northwest Biotherapeutics appears to be the applicant for WO2025106534 and also owns Flaskworks, it's possible this new patent represents an advancement or related development within their overall cell therapy manufacturing strategy.

[hyperopia]

beartrap, this is the new & improved Flaskworks Eden system that is considerably larger than the previous version that Lykiri found a couple years ago. This latest version has multiple actuators that can shake and spin the cartridge containing the cells, and appears to have the ability to use hydraulic pressure to remove the cells from the bottom of the cartridge. This was the major obstacle (automated removal of the sticky cells from the culture vessel without damaging them or using reagents) that proved to be extremely difficult to overcome.

This patent also displays the results of some of the bioassays (identity, purity, etc.) for the final product to prove that the automated procedure can duplicate (and actually improve) the results of the manual method of production.

I’m guessing that this is the version that they hired a contractor to manufacture for initial automated commercial production.

Shoutout to @HenryMuney for finding and posting this!

BTW- StockFollower’s AI summary is not accurate and is misleading, which shows the immense limits of this AI technology. For example, Eden does not “optimize the production of genetically modified immune cells, such as CAR T cells.”